Xenon Pharmaceuticals (XENE)
(Real Time Quote from BATS)
$41.56 USD
+2.19 (5.56%)
Updated Sep 13, 2024 01:20 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Company Summary
Based in Burnaby, Canada, Xenon Pharmaceuticals Inc. is a clinical-stage biotech developing innovative therapies for neurology indications with a focus on epilepsy.
Currently, Xenon has no marketed drug in its portfolio.
Xenon’s pipeline consists only of its lead product candidate, azetukalner, a differentiated Kv7 potassium channel, currently being developed for treating epilepsy and other neurological disorders, including MDD.
In the first quarter of 2023, the company announced discontinuing the clinical development of its second pipeline candidate, XEN496, to prioritize the pediatric development plans for azetukalner.
In ...
Company Summary
Based in Burnaby, Canada, Xenon Pharmaceuticals Inc. is a clinical-stage biotech developing innovative therapies for neurology indications with a focus on epilepsy.
Currently, Xenon has no marketed drug in its portfolio.
Xenon’s pipeline consists only of its lead product candidate, azetukalner, a differentiated Kv7 potassium channel, currently being developed for treating epilepsy and other neurological disorders, including MDD.
In the first quarter of 2023, the company announced discontinuing the clinical development of its second pipeline candidate, XEN496, to prioritize the pediatric development plans for azetukalner.
In December 2019, Xenon entered into a collaboration agreement with Neurocrine Biosciences granting the latter an exclusive license to XEN901, now known as NBI-921352. NBI-921352 is a selective Nav1.6 sodium channel inhibitor. Neurocrine is currently evaluating NBI-921352 in a phase II study to treat patients aged 2-21 years with SCN8A developmental and epileptic encephalopathy (SCN8A-DEE).
Per the terms of the agreement with Neurocrine, Xenon is eligible to receive certain clinical, regulatory, and commercial milestone-based payments, as well as royalties on future sales.
Xenon is also currently collaborating with the Icahn School of Medicine at Mount Sinai to support an ongoing phase II proof-of-concept study of azetukalner for the treatment of MDD in approximately 60 subjects.
With no marketed products in its portfolio, Xenon only generates periodical revenues from its collaboration with Neurocrine. For the full year 2023, Xenon did not generate any revenues. The company recorded revenues of $9.4 million in 2022.
General Information
Xenon Pharmaceuticals Inc
3650 GILMORE WAY
BURNABY, A1 V5G 4W8
Phone: 604-484-3300
Fax: 604-484-3450
Web: http://www.xenon-pharma.com
Email: investors@xenon-pharma.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 11/13/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -0.85 |
Current Year EPS Consensus Estimate | -3.16 |
Estimated Long-Term EPS Growth Rate | 3.50 |
Exp Earnings Date | 11/13/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 39.37 |
52 Week High | 50.99 |
52 Week Low | 27.99 |
Beta | 1.25 |
20 Day Moving Average | 286,766.16 |
Target Price Consensus | 58.04 |
4 Week | 2.93 |
12 Week | 6.15 |
YTD | -14.52 |
4 Week | 1.96 |
12 Week | 3.82 |
YTD | -27.14 |
Shares Outstanding (millions) | 75.76 |
Market Capitalization (millions) | 2,982.85 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | -4.17% |
vs. Previous Quarter | -20.97% |
vs. Previous Year | NA% |
vs. Previous Quarter | NA% |
Price/Book | 3.52 |
Price/Cash Flow | NA |
Price / Sales | NA |
6/30/24 | -24.16 |
3/31/24 | -24.35 |
12/31/23 | -25.18 |
6/30/24 | -23.15 |
3/31/24 | -23.28 |
12/31/23 | -23.99 |
6/30/24 | 23.27 |
3/31/24 | 31.82 |
12/31/23 | 23.65 |
6/30/24 | 23.27 |
3/31/24 | 31.82 |
12/31/23 | 23.65 |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | 11.18 |
3/31/24 | 11.76 |
12/31/23 | 14.18 |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | 0.00 |
3/31/24 | 0.00 |
12/31/23 | 0.00 |
6/30/24 | 0.00 |
3/31/24 | 0.00 |
12/31/23 | 0.00 |